Humans ; Physicians ; Professional-Patient Relations

Drug-Related Side Effects and Adverse Reactions ; Humans

Carcinoma, Squamous Cell ; metabolism ; pathology ; Chemokine CCL2 ; metabolism ; Fibroblast Growth Factor 7 ; metabolism ; Fibroblasts ; metabolism ; pathology ; Gelatinases ; metabolism ; Humans ; Membrane Proteins ; metabolism ; Mouth Neoplasms ; metabolism ; pathology ; Neoplasm Invasiveness ; Neoplasm Metastasis ; Serine Endopeptidases ; metabolism

Cephalosporins ; adverse effects ; therapeutic use ; Humans ; Infant, Newborn ; Penicillins ; adverse effects ; therapeutic use ; Skin Tests

Humans ; Recurrence ; Respiratory Tract Infections

Acetaminophen ; therapeutic use ; Child ; Fever ; drug therapy ; Humans ; Ibuprofen ; therapeutic use ; Neonatology

Humans ; Medical Waste Disposal ; Occupational Health

Actinomycosis ; pathology ; Female ; Humans ; Middle Aged ; Tongue Diseases ; microbiology ; pathology

Objective To study the activation of Janus protein tyrosine kinase (JAK)/signal transducer and activator of transcription 1 (STAT1) signaling pathway and its inhibitor-signal transducer and activator of transcription-1(SOCS-1) in patients with systemic lupus erythematosus. Methods A total of 45 patients with active systemic lupus erythematosus (SLE) and 30 healthy controls were randomly selected. Western blot was performed to measure the expression of Stat1 protein and phospho-Stat1 protein (an activated form of Stat1 protein) in the monocytes after stimulation with recombinant high mobility group box1 (rHMGB1) at various time points. Expression of Stat1 protein in the skin or lesional skin was also detected. Phasic expressions of SOCS-1 mRNA in the monocytes after rHMGB1 stimulation were detected by real-time reverse transcription-polymerase chain reaction. SOCS-1 gene expression in the skin or lesional skin was also detected. Results The expression level of Stat1 proteins in the monocytes from patients with SLE was higher than that from healthy controls (t=9.16,P＜0.01) and positively correlated with SLE disease activity index (SLEDAI) (r=0.59,P＜0.01). Expression of phospho-Stat1 in the monocytes from SLE patients was time-dependently upregulated after stimulation with rHMGB1 at various time points, while expression of SOCS-1 mRNA remained unchanged(all P＞0.05). Expressions of phospho-Stat1 protein and SOCS-1 mRNA in the monocytes from healthy controls were increased transiently after stimulation with rHMGB1(all P＜0.05). Both expressions of phospho-Stat1 protein and SOCS-1 gene in the lesional skin from patients with SLE were upregulated compared with those in normal skin from healthy controls (all P＜0.01). Conclusion There are hyperactivation of JAK-STAT1 signaling pathway and negative feedback down-regulation of SOCS-1 in patients with systemic lupus erythematosus. HMGB-1 may be partly involved in the pathogenesis of SLE by the abnormal mediating function of JAK-STAT1 signal transduction pathway.

ObjectiveTo investigate the clinical effect and safety of albumin-bound paclitaxel (Nab-P) as the first-line treatment for advanced primary liver cancer. MethodsA retrospective analysis was performed for the clinical data of 23 patients with advanced primary liver cancer who were admitted to the Department of Medical Oncology in Chinese PLA General Hospital from May 2014 to December 2015. According to the treatment regimen, these patients were divided into observation group and control group. The 12 patients in the observation group were treated with Nab-P, among whom 5 were treated with Nab-P combined with tegafur, gimeracil and oteracil, 5 were treated with Nab-P combined with capecitabine, and 2 were treated with Nab-P alone; the 11 patients in the control group were treated with gemcitabine combined with oxaliplatin. One cycle of the treatment was 21 days for each treatment regimen; therapeutic effect was evaluated every 2 cycles, and adverse events were evaluated every cycle. The chi-square test or the Fisher’s exact test was used for comparison of categorical data between groups, the Kaplan-Meier survival curves were used to analyze progression-free survival, and the log-rank test was used to compare survival rates between groups. ResultsAll the patients were eligible for evaluation of clinical outcome and adverse events. In the observation group, 2 patients achieved partial remission, 7 had a stable disease, and 3 had a progressive disease; in the control group, 2 achieved partial remission, 5 had a stable disease, and 4 had a progressive disease. There was no significant difference in disease control rate between the two groups (75% vs 64%, χ2=0.350, P＞0.05). There was also no significant difference in the median progression-free survival between the two groups ［5.1 (2.7-6.7) months vs 4.3 (2.5-5.4) months, χ2=0.647, P＞0.05］. As for adverse events, no patient experienced serious adverse events, and there were significant differences in the incidence rates of platelet toxicity and increased aspartate aminotransferase between the two groups (χ2=5.490 and 6.135, P=0.036 and 0.027). ConclusionIn the treatment of advanced primary liver cancer, the medication based on Nab-P shows a good clinical effect and tolerable toxic and side effects; however, due to the small sample size in this study, the clinical studies with a large sample size are needed.